ClinicalTrials.gg
Not yet recruitingNCT07949227Updated Nov 19, 2026

AI-assisted CLE for Whole-Chain Diagnosis of the Correa Cascade of Gastric Cancer

An observational study in Gastric Inflammation, Atrophic Gastritis and Intestinal Metaplasia, sponsored by Shandong University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionGastritis, AtrophicRegistry: GastritisReclassifiedWhy we changed it
Registry
Gastritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Gastritis, Atrophic
Why
  1. The study's listed conditions name Gastritis, Atrophic, a narrower term within Gastritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shandong University · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
784
Ages
18 Years and older
Sex
All
01

Study summary

Gastric cancer (GC) is the fifth most common cancer and the fifth leading cause of cancer death worldwide, with 37% of new cases occurring in China. The Correa cascade describes the progression from normal gastric mucosa to chronic inflammation, atrophic gastritis, intestinal metaplasia, intraepithelial neoplasia, and ultimately gastric cancer. Confocal laser endomicroscopy (CLE) enables real-time in vivo "optical biopsy" of gastrointestinal mucosa at subcellular resolution. However, CLE requires a learning curve and interpretation is subject to inter-operator variability. An AI diagnostic system has been developed by Qilu Hospital of Shandong University in collaboration with Wuxi Hisky Medical Technology Co., Ltd. to improve diagnostic performance and assist less experienced endoscopists. This large-sample, prospective, multicenter study aims to evaluate the diagnostic performance of the CLE AI diagnostic system for the whole-chain diagnosis of the gastric cancer Correa cascade, using histopathological diagnosis as the gold standard.

02

Conditions studied

  • Gastric Inflammation
  • Atrophic Gastritis
  • Intestinal Metaplasia
  • Gastric Intraepithelial Neoplasia
  • Gastric Cancer

Browse trials for

03

In context

Gastritis, Atrophic Reclassified

76 studies on the registry are indexed under Gastritis, Atrophic; 37 are open to participants now.

This study's planned enrollment of 784 is above the median of 520 across 55 observational studies indexed under Gastritis, Atrophic.

Browse Gastritis, Atrophic studies →

Lead sponsor

Shandong University is the lead sponsor of 295 studies on the registry; 63 are open to participants now.

Compared within Gastritis, Atrophic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients planned to undergo upper gastrointestinal CLE examination

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned to undergo upper gastrointestinal confocal endoscopy
  • Able to understand and voluntarily sign written

Exclusion criteria

Exclusion Criteria:

  • to anesthesia or gastroscopy, or fluorescein sodium allergy
  • Patients with uncorrectable coagulation disorders
  • Patients with severe cardiopulmonary disease
  • Patients with severe hepatic or renal impairment
  • Pregnant or lactating patients
  • Patients with no suspicious lesions found on endoscopy
  • Patients whose lesion pathology type is not within the Correa sequence (e.g., lymphoma)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
784 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • subjects undergoing CLE examination

    All enrolled subjects undergo the same diagnostic pathway. Each suspicious lesion is examined sequentially with white light endoscopy (WLE), image-enhanced endoscopy (IEE), and confocal laser endomicroscopy (CelTouch® CLE). During CLE examination, the endoscopist provides an independent diagnosis followed by AI-assisted diagnosis.

    Diagnostic Test: AI diagnostic system for CLE

Interventions

  • Diagnostic testAI diagnostic system for CLE

    All enrolled subjects undergo the same diagnostic pathway. Each suspicious lesion is examined sequentially with white light endoscopy (WLE), image-enhanced endoscopy (IEE), and confocal laser endomicroscopy (CelTouch® CLE). During CLE examination, the endoscopist provides an independent diagnosis followed by AI-assisted diagnosis.

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of the CLE AI diagnostic system for the Correa cascade

    Diagnostic accuracy of the CLE AI diagnostic system for diagnosing each category of lesions in the gastric cancer Correa cascade (inflammation, precancerous conditions, precancerous lesions, and cancer), using histopathological diagnosis as the gold standard

    Time frame: 22 months

  2. Diagnostic sensitivity of the CLE AI diagnostic system for the Correa cascade

    Diagnostic sensitivity of the CLE AI diagnostic system for diagnosing each category of lesions in the gastric cancer Correa cascade (inflammation, precancerous conditions, precancerous lesions, and cancer), using histopathological diagnosis as the gold standard

    Time frame: 22 months

  3. Diagnostic specificity of the CLE AI diagnostic system for the Correa cascade

    Diagnostic specificity of the CLE AI diagnostic system for diagnosing each category of lesions in the gastric cancer Correa cascade (inflammation, precancerous conditions, precancerous lesions, and cancer), using histopathological diagnosis as the gold standard

    Time frame: 22 months

Secondary outcomes

  1. The comparison of diagnostic accuracy between AI system and endoscopists

    Comparing the diagnostic accuracy of AI alone, endoscopists alone, and endoscopists using AI for lesion diagnosis, using histopathology as gold standard

    Time frame: 22 months

  2. The comparison of diagnostic sensitivity between AI system and endoscopists

    Comparing the diagnostic sensitivity of AI alone, endoscopists alone, and endoscopists using AI for lesion diagnosis, using histopathology as gold standard

    Time frame: 22 months

  3. The comparison of diagnostic specificity between AI system and endoscopists

    Comparing the diagnostic specificity of AI alone, endoscopists alone, and endoscopists using AI for lesion diagnosis, using histopathology as gold standard

    Time frame: 22 months

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 19, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07949227
Responsible party
Xiuli Zuo (Director of the Department of Gastroenterology, Qilu Hospital of Shandong University) — Principal investigator
First posted
Nov 19, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion